[go: up one dir, main page]

AR076361A1 - Composicion farmaceutica. kit. metodos y sistemas de conversion ascendente de energia no invasivos para la fotobiomodulacion in-situ - Google Patents

Composicion farmaceutica. kit. metodos y sistemas de conversion ascendente de energia no invasivos para la fotobiomodulacion in-situ

Info

Publication number
AR076361A1
AR076361A1 ARP100101318A ARP100101318A AR076361A1 AR 076361 A1 AR076361 A1 AR 076361A1 AR P100101318 A ARP100101318 A AR P100101318A AR P100101318 A ARP100101318 A AR P100101318A AR 076361 A1 AR076361 A1 AR 076361A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical composition
coumarin
agent
nanoparticle
composition according
Prior art date
Application number
ARP100101318A
Other languages
English (en)
Original Assignee
Immunoligtht Llc
Univ Duke
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunoligtht Llc, Univ Duke filed Critical Immunoligtht Llc
Publication of AR076361A1 publication Critical patent/AR076361A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/062—Photodynamic therapy, i.e. excitation of an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
    • A61B5/0071—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence by measuring fluorescence emission
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/48—Diagnostic techniques
    • A61B6/481—Diagnostic techniques involving the use of contrast agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0042—Photocleavage of drugs in vivo, e.g. cleavage of photolabile linkers in vivo by UV radiation for releasing the pharmacologically-active agent from the administered agent; photothrombosis or photoocclusion
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0052—Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0061—5-aminolevulinic acid-based PDT: 5-ALA-PDT involving porphyrins or precursors of protoporphyrins generated in vivo from 5-ALA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0039—Coumarin dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
    • A61L2/0029—Radiation
    • A61L2/0047—Ultraviolet radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/007—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests for contrast media
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/40—Applying electric fields by inductive or capacitive coupling ; Applying radio-frequency signals
    • A61N1/403—Applying electric fields by inductive or capacitive coupling ; Applying radio-frequency signals for thermotherapy, e.g. hyperthermia
    • A61N1/406—Applying electric fields by inductive or capacitive coupling ; Applying radio-frequency signals for thermotherapy, e.g. hyperthermia using implantable thermoseeds or injected particles for localized hyperthermia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/02—Radiation therapy using microwaves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0601—Apparatus for use inside the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/067—Radiation therapy using light using laser light
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/02—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using physical phenomena
    • A61L2/08—Radiation
    • A61L2103/05—
    • A61L2103/09—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2202/00—Aspects relating to methods or apparatus for disinfecting or sterilising materials or objects
    • A61L2202/20—Targets to be treated
    • A61L2202/21—Pharmaceuticals, e.g. medicaments, artificial body parts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2202/00—Aspects relating to methods or apparatus for disinfecting or sterilising materials or objects
    • A61L2202/20—Targets to be treated
    • A61L2202/22—Blood or products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/063—Radiation therapy using light comprising light transmitting means, e.g. optical fibres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/065—Light sources therefor
    • A61N2005/0656—Chemical light sources
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
    • A61N2005/0659—Radiation therapy using light characterised by the wavelength of light used infrared
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
    • A61N2005/0662—Visible light
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/0618—Psychological treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/0622—Optical stimulation for exciting neural tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/0624—Apparatus adapted for a specific treatment for eliminating microbes, germs, bacteria on or in the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Radiology & Medical Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Surgery (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Optics & Photonics (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

Reivindicacion 1: Una composicion farmacéutica para el uso en la fabricacion de un medicamento para modificar una estructura blanco que media o se asocia con una actividad biologica, en donde el tratamiento comprende: colocar una nanopartícula en la vecindad de una estructura blanco en un sujeto que necesita tratamiento, en donde la nanopartícula se configura, después de la exposicion a una primera longitud de onda gamma1, para generar una segunda longitud de onda gamma2 de una radiacion que tiene mayor energía que la primera longitud de onda gamma1, en donde la nanopartícula se configura para emitir luz en la vecindad o en la estructura blanco después de la interaccion con una energía de iniciacion que tiene una energía en el rango de gamma1; y aplicar la energía de iniciacion que incluye dicha primera longitud de onda gamma1 desde una fuente de energía de iniciacion al sujeto, en donde la luz emitida que incluye dicha segunda longitud de onda gamma2 se pone en contacto en forma directa o indirecta con la estructura blanco e induce un cambio predeterminado en dicha estructura blanco in situ, en donde dicho cambio predeterminado modifica la estructura blanco y modula la actividad biologica de la estructura blanco. Reivindicacion 3: La composicion farmacéutica de cualquiera de las reivindicaciones precedentes, en donde la nanopartícula comprende un nucleo dieléctrico. Reivindicacion 30: La composicion farmacéutica de cualquiera de las reivindicaciones precedentes, en donde: la nanopartícula comprende una partícula dieléctrica sub 1000 nm; la partícula dieléctrica comprende al menos un compuesto seleccionado del grupo que consiste en Y2O3, Y2O2S, NaYF4, NaYbF4, YAG, YAP, Nd2O3, LaF3, LaCl3, La2O3, TiO2, LuPO4, YVO4, YbF3, YF3, YbF3 dopado con Na, SiO2 y sus aleaciones o capas; la partícula dieléctrica comprende un dopante que comprende Er, Eu, Yb, Tm, Nd, Tb, Ce, Y, U, Pr, La, Gd u otras especies de tierras raras o una combinacion de estos; el dopante tiene una concentracion de 0,01 %-50% en mol; y la estructura metálica incluye al menos un elemento seleccionado del grupo que consiste en Au, Ag, Cu, Ni, Pt, Pd, Co, Ru, Rh, Al, Ga, y sus aleaciones o capas. Reivindicacion 35: La composicion farmacéutica de cualquiera de las reivindicaciones precedentes, en donde la nanopartícula comprende una aleacion de dos o más materiales, en donde la aleacion tiene una composicion entre los dos o mas materiales ajustada a un valor de composicion donde la excitacion de la aleacion a la primera longitud de onda gamma1 produce emision en la segunda longitud de onda gamma2. Reivindicacion 36: La composicion farmacéutica de acuerdo con la reivindicacion 35, en donde la aleacion comprende al menos uno de: una aleacion de sulfuro de cinc y seleniuro de cinc; o una aleacion de sulfuro de cinc y sulfuro de cadmio. Reivindicacion 50: La composicion farmacéutica de acuerdo con cualquiera de las reivindicaciones 1-48, donde la resonancia de plasmon superficial están en la banda de frecuencia NIR y la emision está en la banda de frecuencia ultravioleta. Reivindicacion 64: La composicion farmacéutica de acuerdo con cualquiera de las reivindicaciones 62-63, en donde el receptor comprende un agente farmacéutico activable. Reivindicacion 65: La composicion farmacéutica de acuerdo con la reivindicacion 64, en donde el agente farmacéutico activable es un agente fotoactivable que comprende al menos uno del agente seleccionado del grupo que consiste en psoraleno, colesteriloleato de pireno, acridina, porfirina, fluoresceína, rodamina, 16-diazorcortisona, etidio, complejos de metales de transicion de bleomicina, complejos de metales de transicion de complejos de organoplatino de deglicobleomicina, aloxacinas, vitaminas K, vitamina L, metabolitos de vitaminas, precursores de vitamina, naftoquinonas, naftalenos, naftoles y sus derivados que tienen conformaciones moleculares planas, porforinporfirinas, colorantes y derivados de fenotiacinas, cumarinas, quinolonas, quinonas, y antraquinonas, y porficeno, rubirina, rosarina, hexafirina, sapfirina, clorofila, clorina, ftalocinina, porfiracina, bacterioclorofila, feofitina, componente basados en macrocíclicos y texafirina, y un derivado metalado de estos. Reivindicacion 66: La composicion farmacéutica de acuerdo con la reivindicacion 62, en donde el receptor comprende al menos uno de un colorante láser, un fluoroforo, un luminoforo, o un fosforo. Reivindicacion 67: La composicion farmacéutica de acuerdo con la reivindicacion 66, en donde el receptor comprende al menos un colorante láser, en donde el al menos un colorante láser comprende al menos un agente seleccionado del grupo que consiste en p-terfenilo, sulforodamina B, p-cuaterfenilo, Rodamina 101, curbostirilo 124, perclorato de violeta cresilo, popop, yoduro de DODC, cumarina 120, sulforodamina 101, cumarina 2, perclorato de oxazina 4, cumarina 339, PCM, cumarina 1, perclorato de oxazina 170, cumarina 138, perclorato azul Nilo A, cumarina 106, perclorato de oxatina 1, cumarina 102, piridina 1, cumarina 314T, estirilo 7, cumarina 338, yoduro de HIDC, cumarina 151, yoduro de PTPCm, cumarina 4, criptocianina, cumarina 314, yoduro de DOTC, cumarina 30, yoduro de HITC, cumarina 500, perclorato de HITC, cumarina 307, yoduro de PTTC, cumarina 334, perclorato de DTTC, cumarina 7, IR-144, cumarina 343, perclorato de HDITC, cumarina 337, IR-NO, cumarina 6, IR-132, cumarina 152, IR-125, cumarina 153, boro-dipirrometer, HPTS, fluoresceína, rodamina 110, 2, 7- diclorofluoresceína, rodamina 65, y perclorato de rodamina 19, rodamina b, y sus derivados. Reivindicacion 68: La composicion farmacéutica de cualquiera de las reivindicaciones precedentes, en donde la nanopartícula además comprende un biorreceptor unido a la nanopartícula, y en donde el biorreceptor es al menos una sonda seleccionada del grupo que consiste en una sonda de anticuerpo, una sonda de ADN, una sonda de sacárido, una sonda de péptido, y una sonda de enzima. Reivindicacion 69: La composicion farmacéutica de cualquiera de las reivindicaciones precedentes, en donde la nanopartícula además comprende un agente secundario unido a la nanopartícula, y en donde el agente secundario es al menos un agente seleccionado del grupo que consiste en emisores secundarios, agentes citotoxicos, agentes de imagen de resonancia magnética (MRI), agentes de tomografía de emision de positrones (PET) y agente de terapia fotodinámica (PDT). Reivindicacion 125: La composicion farmacéutica de cualquiera de las reivindicaciones precedentes, en donde el al menos un agente modulador de energía es uno o más miembros seleccionados del grupo que consiste en una nanopartícula metálica fluorescente biocompatible, nanopartícula de oxido metálico fluorescente, molécula de colorante fluorescente, nanopartícula de oro, nanopartícula de plata, nanopartícula de plata recubierta de oro, un punto cuántico soluble en agua encapsulado por dendrímeros de poliamidoamina, una luciferasa, una molécula fosforescente biocompatible, una molécula recolectora de energía electromagnética combinada y un quelato lantánido que exhibe luminiscencia intensa. Reivindicacion 134: La composicion farmacéutica de cualquiera de las reivindicaciones precedentes que además comprende aplicar un agente activo plasmonico. Reivindicacion 136: La composicion farmacéutica de acuerdo con la reivindicacion 134, en donde el agente activo plasmonico es una sonda para terapia fotoespectral mejorada con plasmonicos (PEPST), que comprende: a) al menos una nanopartícula de metal, b) al menos un agente farmacéutico activable, y c) opcionalmente, al menos un agente modulador de energía. Reivindicacion 145: La composicion farmacéutica de acuerdo con la reivindicacion 134, en donde el agente activo plasmonico es una sonda de PEPST que comprende multiples estructuras para diferentes regimenes de activacion plasmonica. Reivindicacion 146: La composicion farmacéutica de acuerdo con la reivindicacion 145, en donde dicho régimen es al menos uno seleccionado del grupo que consiste en NIR y rayos X. Reivindicacion 157: La composicion farmacéutica de acuerdo con la reivindicacion 136, en donde el agente farmacéutico activable se administra a un blanco y se libera del agente activo plasmonico por radiacion fotonica o ultrasonido, y en donde el agente activo plasmonico es una sonda de PEPST. Reivindicacion 168: La composicion farmacéutica de acuerdo con la reivindicacion 134, en donde el agente activo plasmonico es una sonda de fototerapia mejorada con plasmon-exciton (EPEP) que comprende al menos una nanoestructura metálica activa plasmonica, al menos un material del agente modulador de energía generador de excitones, y el al menos un agente farmacéutico activable, en donde dicha nanoestructura metálica y dicho material produce acoplamiento de plasmon-exciton (EPC). Reivindicacion 192: La composicion farmacéutica de acuerdo con la reivindicacion 100, en donde la afeccion, trastorno o enfermedad es un trastorno de proliferacion celular que es al menos un miembro seleccionado del grupo que consiste en cáncer, infeccion bacteriana, infeccion viral, respuesta de rechazo inmune, trastornos autoinmunes, afecciones aplásicas y sus combinaciones. Reivindicacion 193: La composicion farmacéutica de acuerdo con la reivindicacion 100, en donde dicha afeccion, trastorno o enfermedad se selecciona del grupo que consiste en ablacion cardíaca, afecciones fotoangioplásicas, hiperplasia de la íntima, fístula arteriovenosa, degeneracion macular, psoriasis, acné, alopecia areata, hemangiomas, eliminacion del pelo, enfermedades autoinmunes, artritis reumatoide e inflamatoria, trastornos/afecciones conductuales y cognitivos, afecciones articulares, y afecciones de ganglios linfáticos. Reivindicacion 196: La composicion farmacéutica de cualquiera de las reivindicaciones precedentes, en donde al menos un agente farmacéutico activable es uno seleccionado de 7,8-dimetil-10-ribitilo, isoaloxacina, 7,8,10-trimetili
ARP100101318A 2009-04-21 2010-04-21 Composicion farmaceutica. kit. metodos y sistemas de conversion ascendente de energia no invasivos para la fotobiomodulacion in-situ AR076361A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17115209P 2009-04-21 2009-04-21

Publications (1)

Publication Number Publication Date
AR076361A1 true AR076361A1 (es) 2011-06-08

Family

ID=43011459

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100101318A AR076361A1 (es) 2009-04-21 2010-04-21 Composicion farmaceutica. kit. metodos y sistemas de conversion ascendente de energia no invasivos para la fotobiomodulacion in-situ

Country Status (7)

Country Link
US (8) US9302116B2 (es)
EP (1) EP2421376B1 (es)
JP (4) JP5908396B2 (es)
AR (1) AR076361A1 (es)
SA (1) SA114350273B1 (es)
TW (1) TWI511756B (es)
WO (1) WO2010123993A1 (es)

Families Citing this family (222)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130274837A1 (en) * 1998-10-23 2013-10-17 Babak Nemati Systems and Methods to Enhance Optical Transparency of Biological Tissues for Photobiomodulation
US20110040295A1 (en) * 2003-02-28 2011-02-17 Photometics, Inc. Cancer treatment using selective photo-apoptosis
US7354433B2 (en) * 2003-02-28 2008-04-08 Advanced Light Technologies, Llc Disinfection, destruction of neoplastic growth, and sterilization by differential absorption of electromagnetic energy
US7520860B2 (en) * 2005-04-13 2009-04-21 Marie G. Johnson Detection of coronary artery disease using an electronic stethoscope
US9238150B2 (en) 2005-07-22 2016-01-19 The Board Of Trustees Of The Leland Stanford Junior University Optical tissue interface method and apparatus for stimulating cells
US10052497B2 (en) 2005-07-22 2018-08-21 The Board Of Trustees Of The Leland Stanford Junior University System for optical stimulation of target cells
US20070053996A1 (en) 2005-07-22 2007-03-08 Boyden Edward S Light-activated cation channel and uses thereof
US9274099B2 (en) 2005-07-22 2016-03-01 The Board Of Trustees Of The Leland Stanford Junior University Screening test drugs to identify their effects on cell membrane voltage-gated ion channel
US8926959B2 (en) 2005-07-22 2015-01-06 The Board Of Trustees Of The Leland Stanford Junior University System for optical stimulation of target cells
US10022457B2 (en) * 2005-08-05 2018-07-17 Gholam A. Peyman Methods to regulate polarization and enhance function of cells
US8398692B2 (en) 2007-01-10 2013-03-19 The Board Of Trustees Of The Leland Stanford Junior University System for optical stimulation of target cells
US20120283802A1 (en) * 2007-01-17 2012-11-08 Chih-Ching Lin Far-infrared radiation in use of improving patency of arteriovenous fistula, decreasing failure of arteriovenous fistula maturation, and preventing and/or ameliorating peripheral artery diseases
US8401609B2 (en) 2007-02-14 2013-03-19 The Board Of Trustees Of The Leland Stanford Junior University System, method and applications involving identification of biological circuits such as neurological characteristics
WO2008106694A2 (en) 2007-03-01 2008-09-04 The Board Of Trustees Of The Leland Stanford Junior University Systems, methods and compositions for optical stimulation of target cells
US8376013B2 (en) 2008-03-11 2013-02-19 Duke University Plasmonic assisted systems and methods for interior energy-activation from an exterior source
US9488916B2 (en) * 2007-04-08 2016-11-08 Immunolight, Llc. Interior energy-activation of photo-reactive species inside a medium or body
US10441810B2 (en) 2007-04-08 2019-10-15 Immunolight, Llc X-ray psoralen activated cancer therapy (X-PACT)
WO2017070197A1 (en) 2015-10-19 2017-04-27 Immunolight, Llc X-ray psoralen activated cancer therapy (x-pact)
US10596387B2 (en) * 2007-04-08 2020-03-24 Immunolight, Llc. Tumor imaging with X-rays and other high energy sources using as contrast agents photon-emitting phosphors having therapeutic properties
US10035027B2 (en) 2007-10-31 2018-07-31 The Board Of Trustees Of The Leland Stanford Junior University Device and method for ultrasonic neuromodulation via stereotactic frame based technique
US10434327B2 (en) 2007-10-31 2019-10-08 The Board Of Trustees Of The Leland Stanford Junior University Implantable optical stimulators
US9907976B2 (en) 2011-07-08 2018-03-06 Immunolight, Llc Phosphors and scintillators for light stimulation within a medium
US20100004623A1 (en) * 2008-03-27 2010-01-07 Angiodynamics, Inc. Method for Treatment of Complications Associated with Arteriovenous Grafts and Fistulas Using Electroporation
ES2608498T3 (es) 2008-04-23 2017-04-11 The Board Of Trustees Of The Leland Stanford Junior University Sistemas, métodos y composiciones para la estimulación óptica de células diana
CN102159713A (zh) 2008-05-20 2011-08-17 Eos神经科学公司 用于递送光敏蛋白的载体和使用方法
EP2294208B1 (en) 2008-05-29 2013-05-08 The Board of Trustees of The Leland Stanford Junior University Cell line, system and method for optical control of secondary messengers
CA2728238C (en) 2008-06-17 2019-03-12 M. Bret Schneider Methods, systems and devices for optical stimulation of target cells using an optical transmission element
CA2728402A1 (en) 2008-06-17 2009-12-23 The Board Of Trustees Of The Leland Stanford Junior University Apparatus and methods for controlling cellular development
WO2010006049A1 (en) 2008-07-08 2010-01-14 The Board Of Trustees Of The Leland Stanford Junior University Materials and approaches for optical stimulation of the peripheral nervous system
NZ602416A (en) 2008-11-14 2014-08-29 Univ Leland Stanford Junior Optically-based stimulation of target cells and modifications thereto
US8632534B2 (en) 2009-04-03 2014-01-21 Angiodynamics, Inc. Irreversible electroporation (IRE) for congestive obstructive pulmonary disease (COPD)
AR076361A1 (es) * 2009-04-21 2011-06-08 Immunoligtht Llc Composicion farmaceutica. kit. metodos y sistemas de conversion ascendente de energia no invasivos para la fotobiomodulacion in-situ
US9155471B2 (en) * 2009-05-27 2015-10-13 Lumicell, Inc'. Methods and systems for spatially identifying abnormal cells
WO2010138919A2 (en) 2009-05-28 2010-12-02 Angiodynamics, Inc. System and method for synchronizing energy delivery to the cardiac rhythm
US9895189B2 (en) 2009-06-19 2018-02-20 Angiodynamics, Inc. Methods of sterilization and treating infection using irreversible electroporation
US8321010B2 (en) * 2009-09-04 2012-11-27 Konstantin Georgievich Korotkov Method for determining the condition of a biological object and device for making same
WO2011038111A1 (en) 2009-09-23 2011-03-31 Crystalplex Corporation Passivated nanoparticles
US8715150B2 (en) 2009-11-02 2014-05-06 Pulse Therapeutics, Inc. Devices for controlling magnetic nanoparticles to treat fluid obstructions
TWI572389B (zh) * 2009-11-10 2017-03-01 伊穆諾萊特公司 用於產生介質中之改變之儀器組及系統、用於產生光或固化之系統、輻射固化或可固化物品、微波或rf接受器及用於治療或診斷之系統
EP2509508A4 (en) * 2009-12-08 2015-11-18 Aum Cardiovascular Inc SYSTEMS AND METHOD FOR DETECTING HEART CIRCULAR DISEASES
US9034204B2 (en) * 2009-12-16 2015-05-19 The Regents Of The University Of California Gold coating of rare earth nano-phosphors and uses thereof
JP5866332B2 (ja) 2010-03-17 2016-02-17 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 感光性イオンを通過させる分子
AU2011232296B2 (en) * 2010-03-22 2013-09-12 Alpharet Pty Ltd Laser immunotherapy
US20130225664A1 (en) 2010-04-05 2013-08-29 Alan Horsager Methods and compositions for decreasing chronic pain
US20110313407A1 (en) * 2010-06-18 2011-12-22 Rafailov Edik U Quantum-dot laser diode
ES2780930T3 (es) 2010-08-27 2020-08-27 Sebacia Inc Composiciones y métodos para termomodulación dirigida
US9572880B2 (en) 2010-08-27 2017-02-21 Sienna Biopharmaceuticals, Inc. Ultrasound delivery of nanoparticles
EP2621736A4 (en) * 2010-10-01 2016-03-02 Intelligent Material Solutions Inc MORPHOLOGICAL AND SIZE-UNIFORM MONODISPERSION PARTICLES AND THEIR FORMED SELF-ASSEMBLY
EP2627274B1 (en) 2010-10-13 2022-12-14 AngioDynamics, Inc. System for electrically ablating tissue of a patient
WO2012051599A2 (en) 2010-10-15 2012-04-19 Eos Neuroscience, Inc. Modulation neural pathways
JP6355335B2 (ja) 2010-11-05 2018-07-11 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 報酬関連行動の光遺伝学的制御
US10568307B2 (en) 2010-11-05 2020-02-25 The Board Of Trustees Of The Leland Stanford Junior University Stabilized step function opsin proteins and methods of using the same
CN106947741A (zh) 2010-11-05 2017-07-14 斯坦福大学托管董事会 光活化嵌合视蛋白及其使用方法
JP6155192B2 (ja) 2010-11-05 2017-06-28 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 光により制御される中枢神経系（ｃｎｓ）機能不全
WO2012061681A1 (en) 2010-11-05 2012-05-10 The Board Of Trustees Of The Leland Stanford Junior University. Control and characterization of memory function
AU2011323231B2 (en) * 2010-11-05 2016-01-07 The Board Of Trustees Of The Leland Stanford Junior University Upconversion of light for use in optogenetic methods
US8696722B2 (en) 2010-11-22 2014-04-15 The Board Of Trustees Of The Leland Stanford Junior University Optogenetic magnetic resonance imaging
IT1403160B1 (it) * 2010-12-06 2013-10-04 Fond Istituto Italiano Di Tecnologia Procedimento di sintesi di nanoparticelle d'oro stellate aventi dimensioni e ramificazioni controllate e nanoparticelle d'oro stellate così ottenute
US9314304B2 (en) 2010-12-08 2016-04-19 Lumicell, Inc. Methods and system for image guided cell ablation with microscopic resolution
WO2012083133A2 (en) 2010-12-16 2012-06-21 The Regents Of The University Of California Metal coating of rare earth nano-phosphors and uses thereof
US8802234B2 (en) 2011-01-03 2014-08-12 Imra America, Inc. Composite nanoparticles and methods for making the same
CN102161892B (zh) * 2011-02-21 2013-07-10 上海洞舟实业有限公司 一种用于x射线记忆成像的荧光材料
CN102544177B (zh) * 2011-03-30 2014-06-25 郑州大学 用于太阳电池的等离子体激元增强上转换器及其制备方法
WO2012145671A1 (en) * 2011-04-20 2012-10-26 The Trustees Of The University Of Pennsylvania Radioisotope-photodynamic therapy for cancer treatment
TWI458504B (zh) 2011-05-02 2014-11-01 Univ Nat Cheng Kung 經皮藥物釋放貼片及利用近紅外光控制其藥物釋放之方法
CN102778567B (zh) * 2011-05-12 2015-05-06 中国科学院生物物理研究所 一种双功能肿瘤诊断试剂及方法
EP2721633B1 (en) * 2011-06-20 2021-05-05 Crystalplex Corporation Stabilized nanocrystals
US20120330291A1 (en) * 2011-06-24 2012-12-27 The Regents Of The University Of California Nonlinear optical photodynamic therapy (nlo-pdt) of the cornea
WO2013012986A1 (en) * 2011-07-19 2013-01-24 Brown Joe D Method and apparatus for distinguishing radiation emitted by targets and non-targets during surgical laser procedures
EP2736406B1 (en) 2011-07-25 2019-09-04 NeuroNexus Technologies, Inc. Neuromodulation transfection system with means for active fluid delivery
US10493297B2 (en) 2011-07-25 2019-12-03 Neuronexus Technologies, Inc. Neuromodulation transfection system with passive fluid delivery
EP2736402B1 (en) 2011-07-25 2018-01-10 NeuroNexus Technologies, Inc. Opto-electrical device and method for artifact reduction
KR20130015634A (ko) * 2011-08-04 2013-02-14 삼성전자주식회사 자성 나노입자의 응집을 이용한 바이오센서 및 그의 검출 방법
US9078665B2 (en) 2011-09-28 2015-07-14 Angiodynamics, Inc. Multiple treatment zone ablation probe
US9267889B1 (en) * 2011-10-12 2016-02-23 Stc.Unm High efficiency light absorbing and light emitting nanostructures
RU2475493C1 (ru) * 2011-11-23 2013-02-20 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Российский университет дружбы народов" (РУДН) Активирующий люминесценцию белка гидридный комплекс
JP6406581B2 (ja) 2011-12-16 2018-10-17 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー オプシンポリペプチドおよびその使用法
SG10201604680UA (en) * 2011-12-19 2016-07-28 Univ Nanyang Tech Synthesis of upconversion nanocomposites for photodynamic therapy
US9414881B2 (en) 2012-02-08 2016-08-16 Angiodynamics, Inc. System and method for increasing a target zone for electrical ablation
EP2817068B1 (en) 2012-02-21 2017-04-12 The Board of Trustees of the Leland Stanford Junior University Compositions for treating neurogenic disorders of the pelvic floor
WO2013151772A1 (en) * 2012-04-06 2013-10-10 The Regents Of The University Of California Geometry enhancement of nanoscale energy deposition by x-rays
KR101932727B1 (ko) 2012-05-07 2018-12-27 삼성전자주식회사 범프 구조물, 이를 갖는 반도체 패키지 및 이의 제조 방법
US9478692B1 (en) 2012-05-10 2016-10-25 Lackheed Martin Corporation X-ray multiband emission and conversion
US9432587B1 (en) 2012-05-10 2016-08-30 Lockheed Martin Corporation Near-field enhanced photon conversion
US9521336B1 (en) * 2012-05-10 2016-12-13 Lockheed Martin Corporation Multi-spectral photon converting imaging apparatus
US9883878B2 (en) 2012-05-15 2018-02-06 Pulse Therapeutics, Inc. Magnetic-based systems and methods for manipulation of magnetic particles
US9555132B2 (en) * 2012-06-20 2017-01-31 The Trustees Of The University Of Pennsylvania Water-soluble nanoparticles
US20140051974A1 (en) 2012-08-15 2014-02-20 Aspect Imaging Ltd. System and method for mri imaging using polarized light
HK1210913A1 (en) * 2012-08-31 2016-05-13 索隆-基特林癌症研究协会 Particles, methods and uses thereof
US9480855B2 (en) 2012-09-26 2016-11-01 DePuy Synthes Products, Inc. NIR/red light for lateral neuroprotection
BR112015006873A2 (pt) 2012-09-27 2017-07-04 Rhodia Operations processo para produzir nanoestruturas de prata e copolímero útil em tal processo
WO2014058904A1 (en) 2012-10-11 2014-04-17 Nanocomposix, Inc. Silver nanoplate compositions and methods
US9091766B2 (en) * 2012-10-16 2015-07-28 Nanoptics, Incorporated Method and apparatus for neutron detection utilizing Pulse Height Discrimination and Pulse Shape Discrimination
US20140125532A1 (en) * 2012-11-08 2014-05-08 University Of Utah Tattooed antennas
JP6483023B2 (ja) 2012-12-06 2019-03-13 エンリヴェックス セラピューティクス リミテッド 治療用アポトーシス細胞調製物、その製造方法及びその使用
AU2013361366B2 (en) 2012-12-19 2018-10-18 Sloan-Kettering Institute For Cancer Research Multimodal particles, methods and uses thereof
US9888956B2 (en) 2013-01-22 2018-02-13 Angiodynamics, Inc. Integrated pump and generator device and method of use
JP6635791B2 (ja) 2013-02-20 2020-01-29 スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ 広視野ラマン撮像装置および関連方法
US11759650B2 (en) 2013-03-11 2023-09-19 NeuroEM Therapeutics, Inc. Immunoregulation, brain detoxification, and cognitive protection by electromagnetic treatment
US12318624B2 (en) 2013-03-11 2025-06-03 NeuroEM Therapeutics, Inc. Brain immunoregulation through transcranial electromagnetic treatment
US11813472B2 (en) 2013-03-11 2023-11-14 NeuroEM Therapeutics, Inc. Systems for sensing proper emitter array placement
US11911629B2 (en) 2013-03-11 2024-02-27 NeurEM Therapeutics, Inc. Treatment of primary and metastatic brain cancers by transcranial electromagnetic treatment
US11752356B2 (en) 2013-03-11 2023-09-12 NeuroEM Therapeutics, Inc. Systems for controlling power to differently loaded antenna arrays
EP4449997A3 (en) 2013-03-14 2025-01-15 Lumicell, Inc. Medical imaging device and methods of use
AU2014227600B2 (en) 2013-03-15 2018-10-04 The Board Of Trustees Of The Leland Stanford Junior University Optogenetic control of behavioral state
US9636380B2 (en) 2013-03-15 2017-05-02 The Board Of Trustees Of The Leland Stanford Junior University Optogenetic control of inputs to the ventral tegmental area
CA2908864A1 (en) 2013-04-29 2014-11-06 The Board Of Trustees Of The Leland Stanford Junior University Devices, systems and methods for optogenetic modulation of action potentials in target cells
US9382254B2 (en) 2013-05-07 2016-07-05 Galapagos Nv Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis
US10420471B2 (en) * 2013-06-13 2019-09-24 Research Foundation Of The City University Of New York Method of deep tissue imaging using multi-photon excitation of a fluorophore
CN103290019B (zh) * 2013-06-14 2014-03-12 严鹏科 一种动脉粥样硬化的靶向适配子及其制备方法和应用
WO2014210588A1 (en) * 2013-06-28 2014-12-31 North Carolina State University Systems and methods for determining sleep patterns and circadian rhythms
US9630172B2 (en) * 2013-07-03 2017-04-25 Gwangju Institute Of Science And Technology Photocatalyst complex
CN105829538A (zh) 2013-08-14 2016-08-03 小利兰·斯坦福大学托管委员会 用于控制疼痛的组合物和方法
US10064940B2 (en) 2013-12-11 2018-09-04 Siva Therapeutics Inc. Multifunctional radiation delivery apparatus and method
CN105939708A (zh) * 2014-01-06 2016-09-14 新加坡国立大学 包覆TiO2的上转换纳米颗粒均匀核壳结构及其应用
US10912947B2 (en) 2014-03-04 2021-02-09 Memorial Sloan Kettering Cancer Center Systems and methods for treatment of disease via application of mechanical force by controlled rotation of nanoparticles inside cells
CN103980904B (zh) * 2014-03-27 2016-04-27 中国科学院福建物质结构研究所 一种氟化钇锂纳米复合材料及其制备方法和在光动力学治疗中的应用
WO2015153522A1 (en) * 2014-03-31 2015-10-08 Purdue Research Foundation Device and method to control release of compound
EP3134122B1 (en) * 2014-04-22 2020-06-17 Immunolight, Llc. Tumor imaging using photon-emitting phosphors having therapeutic properties
US10525279B2 (en) 2014-04-29 2020-01-07 Theralase Technologies, Inc. Apparatus and method for multiwavelength photodynamic therapy
US10995267B2 (en) 2014-05-29 2021-05-04 Crystalplex Corporation Dispersion system for quantum dots having organic coatings comprising free polar and non-polar groups
US10828400B2 (en) 2014-06-10 2020-11-10 The Research Foundation For The State University Of New York Low temperature, nanostructured ceramic coatings
JP2017523181A (ja) 2014-07-28 2017-08-17 メモリアル スローン−ケタリング キャンサー センター 医療用同位体のためのユニバーサル結合剤としての金属（メタロイド）カルコゲンナノ粒子
US11534622B2 (en) * 2014-08-18 2022-12-27 Immunolight, Llc Non-invasive systems and methods for selective activation of photoreactive responses
US12114911B2 (en) 2014-08-28 2024-10-15 Angiodynamics, Inc. System and method for ablating a tissue site by electroporation with real-time pulse monitoring
CN104384494B (zh) * 2014-10-22 2016-11-23 中国科学技术大学 Re-1涂层稀土纳米颗粒减少其诱发的炎症效应
ES2817748T3 (es) * 2015-01-08 2021-04-08 Purdue Research Foundation Formulaciones no tóxicas de nanopartículas radioluminiscentes para usar como agentes radiosensibilizantes del cáncer
WO2016115225A1 (en) 2015-01-14 2016-07-21 Immunolight, Llc. Non-invasive systems and methods for treatment of a host carrying a virus with photoactivatable drugs
KR101701885B1 (ko) * 2015-01-21 2017-02-02 광주과학기술원 업컨버팅 나노입자 및 특이적 리셉터를 포함하는 당뇨병 진단용 복합체
US9956426B2 (en) * 2015-02-26 2018-05-01 Amol Punjabi Upconverting nanoparticles
US10018608B2 (en) * 2015-02-27 2018-07-10 Vitaly Talyansky System to authenticate and identify items
US9776242B2 (en) * 2015-03-18 2017-10-03 California Institute Of Technology Multiphoton induced direct aggregate scribing
WO2016209936A1 (en) * 2015-06-22 2016-12-29 Duke University Synergistic nanotherapy systems and methods of use thereof
US10568516B2 (en) 2015-06-22 2020-02-25 The Board Of Trustees Of The Leland Stanford Junior University Methods and devices for imaging and/or optogenetic control of light-responsive neurons
CN106316386A (zh) * 2015-06-24 2017-01-11 中国民航大学 一种稀土掺杂铋系层状钙钛矿氧化物铁电上转换材料的制备方法
WO2017004301A1 (en) 2015-07-01 2017-01-05 Memorial Sloan Kettering Cancer Center Anisotropic particles, methods and uses thereof
EP3349736A4 (en) * 2015-09-16 2019-10-16 La Jolla Nanomedical NANOPARTICLE SYSTEM FACED ON CELL ACTIVITY AND METHOD FOR PRODUCING THE NANOPARTICLE SYSTEM
WO2017068586A1 (en) * 2015-10-22 2017-04-27 Jacob Schneiderman Systems and methods for identifying and treating biological materials
AU2016353345B2 (en) 2015-11-12 2021-12-23 University Of Virginia Patent Foundation Compositions and methods for vas-occlusive contraception and reversal thereof
US11197615B2 (en) 2015-12-31 2021-12-14 Research Foundation Of The City University Of New York Noninvasive electroactive photonic protein nanosensor with polymer photovoltaic optics for memory transduction using organic and inorganic elements as platforms
AU2017213801B2 (en) 2016-02-02 2022-04-14 Duke University Phosphor-containing drug activator, suspension thereof, system containing the suspension, and methods for use
WO2017176380A1 (en) * 2016-02-22 2017-10-12 The General Hospital Corporation Systems and methods for selective targeting of structural features in treating skin conditions
KR101908774B1 (ko) * 2016-03-22 2018-10-16 주식회사 포스코 제일원리 계산을 이용한 상향변환 나노입자 제조 및 응용 기술
WO2017167633A1 (en) 2016-03-31 2017-10-05 Sony Corporation Sensor for the detection of biomolecules
JP7175265B2 (ja) 2016-05-19 2022-11-18 クリスタルプレックス コーポレーション カドミウムフリー量子ドット、調整可能な量子ドット、量子ドット含有ポリマー、それらを含有する物品、フィルム、および３ｄ構造ならびにそれらの作製および使用方法
KR102443267B1 (ko) * 2016-06-17 2022-09-14 쏘흐본느 유니베흐시테 제어된 광도로 물체를 비추는 장치 및 관련 방법
WO2018005195A1 (en) * 2016-06-27 2018-01-04 Nanosys, Inc. Methods for buffered coating of nanostructures
US10944398B2 (en) * 2016-09-30 2021-03-09 Uchicago Argonne, Llc Systems and methods for ultrafast plasmonic response in doped, colloidal nanostructures
US10180618B2 (en) * 2016-11-10 2019-01-15 Elwha Llc Coherent upconversion of light
CN110325110B (zh) 2016-11-10 2022-08-09 纽约州立大学研究基金会 用于气道阻塞的系统、方法和生物标记
US10905492B2 (en) 2016-11-17 2021-02-02 Angiodynamics, Inc. Techniques for irreversible electroporation using a single-pole tine-style internal device communicating with an external surface electrode
JP6867640B2 (ja) * 2016-11-18 2021-05-12 大日本塗料株式会社 殺菌又は除菌方法並びに抗菌剤及びそれを備えた物品
US12383421B2 (en) 2017-01-05 2025-08-12 Contraline, Inc. Contraceptive devices
US10751124B2 (en) 2017-01-05 2020-08-25 Contraline, Inc. Methods for implanting and reversing stimuli-responsive implants
CN118058827A (zh) * 2017-03-03 2024-05-24 明尼苏达大学校董事会 使用压电栓塞材料的材料和治疗
US11294165B2 (en) 2017-03-30 2022-04-05 The Board Of Trustees Of The Leland Stanford Junior University Modular, electro-optical device for increasing the imaging field of view using time-sequential capture
US11207409B2 (en) * 2017-05-31 2021-12-28 Immunolight, Llc X-RAY psoralen activated cancer therapy (X-PACT) with associated treatments
US11331019B2 (en) 2017-08-07 2022-05-17 The Research Foundation For The State University Of New York Nanoparticle sensor having a nanofibrous membrane scaffold
EP3456380A1 (en) * 2017-09-15 2019-03-20 Seaborough Life Science B.V. Material capable of emitting radiation in the uv-b wavelength range
EP3684463B1 (en) 2017-09-19 2025-05-14 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement
CZ2017657A3 (cs) * 2017-10-16 2018-12-19 Fyziologický ústav AV ČR, v. v. i. Liposomová léková forma se světlo-konvertujícími nanočásticemi, její příprava a použití
US11484731B2 (en) * 2017-11-09 2022-11-01 International Business Machines Corporation Cognitive optogenetics probe and analysis
US11717686B2 (en) 2017-12-04 2023-08-08 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to facilitate learning and performance
US11478603B2 (en) 2017-12-31 2022-10-25 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to enhance emotional response
US12280219B2 (en) 2017-12-31 2025-04-22 NeuroLight, Inc. Method and apparatus for neuroenhancement to enhance emotional response
CN108211102B (zh) * 2018-01-02 2021-11-05 汕头高新区梦禾生物科技研究所有限公司 一种面部全自动补水控制方法及其仪器
CN108079297B (zh) * 2018-01-16 2020-06-12 复旦大学 一种上转换发光-热化疗复合纳米探针及其制备方法和联合治疗程序化控制的应用
US11364361B2 (en) 2018-04-20 2022-06-21 Neuroenhancement Lab, LLC System and method for inducing sleep by transplanting mental states
US11918315B2 (en) 2018-05-03 2024-03-05 Pulse Therapeutics, Inc. Determination of structure and traversal of occlusions using magnetic particles
US10752834B2 (en) * 2018-05-17 2020-08-25 Chung Yuan Christian University Composite fluorescent gold nanoclusters with high quantum yield and method for manufacturing the same
US11460403B2 (en) 2018-07-05 2022-10-04 AhuraTech LLC Electroluminescent methods and devices for characterization of biological specimens
US11428656B2 (en) 2018-07-05 2022-08-30 AhuraTech LLC Electroluminescent methods and system for real-time measurements of physical properties
US11393387B2 (en) 2018-07-05 2022-07-19 AhuraTech LLC Open-circuit electroluminescence
KR102582064B1 (ko) * 2018-07-11 2023-09-25 한국과학기술연구원 근적외선 흡수 염료 함유 나노입자, 이의 제조방법, 및 이의 용도
US20210263024A1 (en) * 2018-07-21 2021-08-26 Ilisatech, Inc. Lanthanide nanop article based fluorophores
KR102199502B1 (ko) * 2018-08-28 2021-01-06 국민대학교산학협력단 점막하 박리술용 장치 및 파장 선택적 광흡수율이 조절된 점막하 주입액
US10866484B2 (en) * 2018-09-04 2020-12-15 Abl Ip Holding Llc Light frequency upconversion of laser light, for cleansing
EP3849410A4 (en) 2018-09-14 2022-11-02 Neuroenhancement Lab, LLC SYSTEM AND METHODS FOR ENHANCEMENT OF SLEEP
CN109365800B (zh) * 2018-10-15 2020-09-01 黄河科技学院 一种金纳米三角板-二氧化钛核壳纳米复合体、其制备方法及应用
CN109260603A (zh) * 2018-10-31 2019-01-25 京东方科技集团股份有限公司 利用金属卤化物钙钛矿材料形成激光源的方法、激光治疗装置和系统
WO2020102234A1 (en) 2018-11-13 2020-05-22 Contraline, Inc. Systems and methods for delivering biomaterials
US10873175B2 (en) 2019-01-28 2020-12-22 Abl Ip Holding Llc Light frequency up-conversion of laser light, for producing green or yellow light
US10756243B1 (en) * 2019-03-04 2020-08-25 Chung Yuan Christian University Light-emitting diode package structure and method for manufacturing the same
CA3131865A1 (en) 2019-03-04 2020-09-10 Immunolight, Llc. Energy augment structures for use with energy emitters and collectors
CN114507523B (zh) * 2019-05-21 2023-09-29 淮阴工学院 上转换纳米探针的合成方法
WO2020251975A1 (en) * 2019-06-10 2020-12-17 University Of South Florida Methods for treating cancer using x-ray-induced near infrared photoimmunotherapy
CN110338771B (zh) * 2019-08-05 2024-02-09 潍坊医学院 基于光纤传感器的穿刺针头漏血检测方法和检测电路
CN110938423B (zh) * 2019-08-28 2022-09-23 上海大学 可降解锑包覆稀土上转换的纳米复合结构、制备方法及应用
US10883873B1 (en) * 2019-10-17 2021-01-05 King Fahd University Of Petroleum And Minerals Rotating sample platform for SERS analysis
CN110646418B (zh) * 2019-10-24 2021-10-15 福建医科大学 以纳米金为显色探针的钪离子快速测定方法
CN111024672B (zh) * 2020-01-06 2021-06-11 云南大学 一种基于荧光钙钛矿液液萃取检测汞离子的方法
KR20230020382A (ko) * 2020-03-05 2023-02-10 얀크 테크놀로지스, 인크. 높은 고유 품질 수신기 구성
CN111408081A (zh) * 2020-03-06 2020-07-14 浙江雷纹电子科技有限公司 新冠病毒颗粒浓度检测智能口罩及其检测方法
US20230347181A1 (en) * 2020-08-14 2023-11-02 Universidad De Granada A medical apparatus for the non-invasive transmission of focussed shear waves to impact cellular behaviour
US20230313032A1 (en) * 2020-08-20 2023-10-05 The Regents Of The University Of Colorado, A Body Corporate Sensitization enhancement of solid-state photonic upconversion
CN112345474B (zh) * 2020-11-11 2022-06-17 昆明理工大学 一种快速检测食品中特丁基对苯二酚的方法
CN112649605B (zh) * 2020-12-14 2022-11-01 哈尔滨理工大学 一种基于NaBiF4上转换纳米粒子的ECL生物传感器
CN112569971B (zh) * 2020-12-17 2022-02-01 武汉大学 一种金属卤化物钙钛矿CsPbX3在光催化仿生生物合成的应用
TWI843989B (zh) 2021-02-19 2024-06-01 美商美威高能離子醫療系統公司 用於粒子治療系統之支架
CN113209124B (zh) * 2021-02-24 2022-04-15 四川大学 Dna四面体在制备预防和治疗1型糖尿病的药物中的用途
WO2022187188A1 (en) * 2021-03-01 2022-09-09 The Research Foundation For The State University Of New York Dual-layer detector system and method for spectral imaging and contrast enhanced digital breast tomosynthesis
US12171443B1 (en) 2021-03-09 2024-12-24 Pulse Therapeutics, Inc. Magnetically controlled flow generation
CN113332460A (zh) * 2021-03-30 2021-09-03 张耀绵 一种含有维生素c溶液的紫外线c波处理方法
EP4340899A4 (en) 2021-05-19 2025-07-09 Univ Georgia NITRIC OXIDE RELEASING DISINFECTION INSERT
CA3211958A1 (en) 2021-05-25 2022-12-01 Nader SHAFI A non-invasive electromagnetic system for the diagnosis and monitoring of in-vivo and ex-vivo skin anomalies
US12007326B2 (en) * 2021-09-10 2024-06-11 Creeled, Inc. Localized surface plasmon resonance for enhanced photoluminescence of lumiphoric materials
KR102702565B1 (ko) * 2021-09-17 2024-09-04 연세대학교 산학협력단 다중 반응 광감응성 나노 복합체 필름 및 이를 이용한 생체 전기 자극 시스템
US12529959B2 (en) * 2021-09-17 2026-01-20 Industry-Academic Cooperation Foundation, Yonsei University Multi-reactive photosensitive nanocomposite film and bioelectric stimulation system using independent multi-states
CN114699561B (zh) * 2021-12-30 2023-03-31 佛山市中医院 一种掺杂钙基材料、骨修复材料及其制备方法
US20250170098A1 (en) * 2022-02-25 2025-05-29 William Marsh Rice University Molecular jackhammer for mechanical destruction of cellular structure
US20250367468A1 (en) * 2022-06-27 2025-12-04 Duke University Nanoplasmonics-enhanced laser therapy systems and methods thereof
US12429426B2 (en) * 2022-06-27 2025-09-30 Duke University Spatially offset hyperspectral imaging systems and methods thereof
CN115252824A (zh) * 2022-07-01 2022-11-01 天津医科大学 用于荧光和磁共振成像引导光热治疗的多功能上转换纳米晶及其制备方法
WO2024091733A2 (en) * 2022-08-28 2024-05-02 North Carolina State University Room-temperature superfluorescence nanocrystals and related methods
WO2024102407A1 (en) * 2022-11-09 2024-05-16 The General Hospital Corporation Systems and methods for long hair transplantation
CN116626288B (zh) * 2023-04-28 2025-09-16 扬州大学 一种基于钙钛矿纳米晶的快速检测癌胚抗原免疫层析试纸条及其制备方法
KR20250012423A (ko) * 2023-07-17 2025-01-24 차의과학대학교 산학협력단 금 나노입자 및 상환변환 나노입자로부터 형성된 일시적 광천공을 위한 나노복합체
WO2025083710A1 (en) * 2023-10-16 2025-04-24 Focelite Goodness India Private Limited An antiviral photosensitive composition and device for potentiating the same
CN117417746B (zh) * 2023-10-19 2025-05-30 中国科学院新疆理化技术研究所 一种强抗干扰、高灵敏检测高氯酸盐的功能化上转换纳米探针
WO2025137477A1 (en) * 2023-12-22 2025-06-26 Cz Biohub Sf, Llc Method and system for force sensors including upconverting nanoparticles in a polymeric host
CN119033669A (zh) * 2024-08-19 2024-11-29 华中科技大学 一种超分子纳米复合微针、其制备方法及应用
CN121041516A (zh) * 2025-11-06 2025-12-02 山东大学 一种光-热-电耦合钛基植入体及其制备方法和应用

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US124A (en) 1837-02-10 Improvement in the machine for weighing heavy bodies
US2000A (en) 1841-03-12 Improvement in the manufacture of starch
US7045A (en) 1850-01-22 Chitck foe
US3688124A (en) 1969-04-30 1972-08-29 Bell Telephone Labor Inc Spatially periodic nonlinear structures for frequency conversion of electromagnetic energy
US4608222A (en) 1971-01-29 1986-08-26 Kms Fusion, Inc. Method of achieving the controlled release of thermonuclear energy
BE815374A (fr) 1973-05-23 1974-09-16 Matiere vitroceramique et procede pour la preparer
US3981736A (en) 1973-05-23 1976-09-21 Ernst Leitz G.M.B.H. Biocompatible glass ceramic material
CH595293A5 (es) 1975-02-20 1978-02-15 Battelle Memorial Institute
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4748120A (en) 1983-05-02 1988-05-31 Diamond Scientific Co. Photochemical decontamination treatment of whole blood or blood components
US4705952A (en) 1985-10-10 1987-11-10 Quantex Corporation Communications apparatus using infrared-triggered phosphor for receiving infrared signals
US4786617A (en) 1986-10-13 1988-11-22 Corning Glass Works Glass-ceramic article, process for its production and thermally crystallizable glass
US4838852A (en) 1987-03-27 1989-06-13 Therakos, Inc. Active specific immune suppression
JPH02149447A (ja) 1988-12-01 1990-06-08 Nippon Electric Glass Co Ltd 歯科用結晶化ガラス
US5216176A (en) 1989-01-23 1993-06-01 Lehigh University 7-alkoxycoumarins, dihydropsoralens, and benzodipyranones as photo-activated therapeutic agents and inhibitors of epidermal growth factor
US4979935A (en) 1989-02-21 1990-12-25 Quantex Corporation Method of photodynamic therapy employing electron trapping material
CA2070389A1 (en) * 1989-10-18 1991-04-19 Ramesh C. Patel Coated particles and methods of coating particles
US5658722A (en) 1990-05-15 1997-08-19 New York Blood Center, Inc. Process for the sterilization of biological compositions using UVA1 irradiation
US5980954A (en) 1992-02-07 1999-11-09 Vasogen Ireland Limited Treatment of autoimmune diseases
US6669965B2 (en) 1992-02-07 2003-12-30 Vasogen Ireland Limited Method of treating atherosclerosis
US6204058B1 (en) 1992-02-07 2001-03-20 Vasogen Ireland Limited Treatment of autoimmune diseases
US5807881A (en) 1992-05-27 1998-09-15 Quadra Logic Technologies, Inc. Method for selectively reducing activated leukocyte cell population
US6235508B1 (en) 1995-06-07 2001-05-22 Baxter International Inc. Method of inactivation of viral and bacterial blood contaminants
US6008211A (en) 1995-07-27 1999-12-28 Pdt Pharmaceuticals, Inc. Photoactivatable compounds comprising benzochlorin and furocoumarin
BR9708468A (pt) 1996-03-29 2000-01-04 Therakos Inc Tratamento de fotoferese de leucocitos.
US5829448A (en) 1996-10-30 1998-11-03 Photogen, Inc. Method for improved selectivity in photo-activation of molecular agents
ATE349697T1 (de) * 1997-02-20 2007-01-15 Univ California Plasmon-schwingteilchen, methode und vorrichtung
US5957960A (en) 1997-05-05 1999-09-28 Light Sciences Limited Partnership Internal two photon excitation device for delivery of PDT to diffuse abnormal cells
US6609014B1 (en) 1999-04-14 2003-08-19 Qlt Inc. Use of PDT to inhibit intimal hyperplasia
US7123359B2 (en) * 1999-05-17 2006-10-17 Arrowhead Center, Inc. Optical devices and methods employing nanoparticles, microcavities, and semicontinuous metal films
WO2001005001A1 (en) 1999-07-12 2001-01-18 Massachusetts Institute Of Technology Resonant microcavities
US7332344B2 (en) 1999-12-01 2008-02-19 Photonic Research Systems Limited Luminescence assays
CA2399293C (en) 2000-02-08 2012-01-03 Rice University Optically-active nanoparticles for use in therapeutic and diagnostic methods
US6530944B2 (en) * 2000-02-08 2003-03-11 Rice University Optically-active nanoparticles for use in therapeutic and diagnostic methods
US6719778B1 (en) 2000-03-24 2004-04-13 Endovascular Technologies, Inc. Methods for treatment of aneurysms
ATE320605T1 (de) * 2000-05-05 2006-04-15 Dotierte nanoteilchen als biolabel
US6811562B1 (en) 2000-07-31 2004-11-02 Epicor, Inc. Procedures for photodynamic cardiac ablation therapy and devices for those procedures
US20080306471A1 (en) * 2000-12-28 2008-12-11 Palomar Medical Technologies, Inc. Methods and devices for fractional ablation of tissue
US20020127224A1 (en) 2001-03-02 2002-09-12 James Chen Use of photoluminescent nanoparticles for photodynamic therapy
EP1251530A3 (en) * 2001-04-16 2004-12-29 Shipley Company LLC Dielectric laminate for a capacitor
US7501092B2 (en) 2001-06-06 2009-03-10 Nomadics, Inc. Manganese doped upconversion luminescence nanoparticles
US7008559B2 (en) 2001-06-06 2006-03-07 Nomadics, Inc. Manganese doped upconversion luminescence nanoparticles
EP1465699A4 (en) 2001-12-12 2006-05-24 Leon J Lewandowski AUTOIMMUNE STIMULATION BY PHOTOPHORESIS
US20040181344A1 (en) 2002-01-29 2004-09-16 Massachusetts Institute Of Technology Systems and methods for providing diagnostic services
US7112306B2 (en) 2002-05-06 2006-09-26 Carrier Corporation Electrodeless ultraviolet discharge fluid remediation
US6908591B2 (en) 2002-07-18 2005-06-21 Clearant, Inc. Methods for sterilizing biological materials by irradiation over a temperature gradient
AU2003252136A1 (en) * 2002-07-24 2004-02-09 Ptc Therapeutics, Inc. METHODS FOR IDENTIFYING SMALL MOLEDULES THAT MODULATE PREMATURE TRANSLATION TERMINATION AND NONSENSE MEDIATED mRNA DECAY
US6752868B2 (en) 2002-07-31 2004-06-22 Mcnc Research & Development Institute Layer-by-layer assembly of photonic crystals
US7468146B2 (en) 2002-09-12 2008-12-23 Agfa-Gevaert Metal chalcogenide composite nano-particles and layers therewith
US20060160134A1 (en) * 2002-10-21 2006-07-20 Melker Richard J Novel application of biosensors for diagnosis and treatment of disease
US7263259B2 (en) * 2003-02-07 2007-08-28 Zetetic Institute Multiple-source arrays fed by guided-wave structures and resonant guided-wave structure cavities
US20050186565A1 (en) 2003-02-10 2005-08-25 American Environmental Systems, Inc. Method and spectral/imaging device for optochemical sensing with plasmon-modified polarization
US7184203B2 (en) 2003-02-21 2007-02-27 Burgener Ii Robert H Rare earth compounds having photo-luminescent properties and applications thereof
US7297154B2 (en) * 2003-02-24 2007-11-20 Maxwell Sensors Inc. Optical apparatus for detecting and treating vulnerable plaque
SE526027C2 (sv) 2003-05-23 2005-06-14 Gambro Lundia Ab Biokompatibel polymerkomposition, förfarande för beredning av en biokompatibel sampolymerkomposition, artikel med en film av en polymerkomposition och användning av en biokompatibel polymerkomposition för en medicinsk anordning
EP1484379B1 (en) * 2003-06-02 2016-09-21 Sony Deutschland GmbH A composition for photon-energy up-conversion
CN1312479C (zh) * 2003-08-08 2007-04-25 清华大学 一种纳米荧光磁粒及其制备方法
US20080241262A1 (en) * 2004-03-29 2008-10-02 The University Of Houston System Nanoshells and Discrete Polymer-Coated Nanoshells, Methods For Making and Using Same
US20080132886A1 (en) * 2004-04-09 2008-06-05 Palomar Medical Technologies, Inc. Use of fractional emr technology on incisions and internal tissues
FR2869803B1 (fr) 2004-05-10 2006-07-28 Nanobiotix Sarl Particules activables, preparation et utilisations
US20050277709A1 (en) * 2004-05-28 2005-12-15 Fisher William K Polymer layers having infrared absorbing particles
US7604523B1 (en) 2004-06-21 2009-10-20 Imaging Systems Technology Plasma-shell PDP
JP2008510829A (ja) * 2004-08-25 2008-04-10 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン デンドリマーに基づく組成物およびそれらの使用法
JP2008519108A (ja) * 2004-10-29 2008-06-05 モレキュラー プローブス， インコーポレイテッド 官能化蛍光性ナノ結晶、並びにそれらの調製及び使用方法
US7538329B2 (en) 2005-02-02 2009-05-26 Nomadics, Inc. Energy-transfer nanocomposite materials and methods of making and using same
JP4659497B2 (ja) 2005-03-29 2011-03-30 シスメックス株式会社 測定装置の測定に関する設定方法、分析システム、データ処理装置、及びアプリケーションプログラム
US20090116753A1 (en) 2005-09-12 2009-05-07 Ultradots, Inc. Authenticating and identifying objects using nanoparticles
US20090227044A1 (en) 2006-01-26 2009-09-10 Dosi Dosev Microchannel Magneto-Immunoassay
US20100023101A1 (en) 2006-02-03 2010-01-28 University Of Wollongong Biocompatible composites
WO2007103802A2 (en) * 2006-03-03 2007-09-13 William Marsh Rice University Nanorice particles: hybrid plasmonic nanostructures
WO2007115291A2 (en) * 2006-04-04 2007-10-11 Freedom-2, Inc. Tissue markings with discrete absorption particles
US20090263485A1 (en) * 2008-03-01 2009-10-22 Chun Li Targeted hollow gold nanostructures and methods of use
JP5099369B2 (ja) * 2006-05-01 2012-12-19 富士レビオ株式会社 金属コーティングにてカプセル化された非金属蛍光粒子
US20090191128A1 (en) 2006-07-10 2009-07-30 Koninklijke Philips Electronics N.V. Core-shell nanoparticles for thearapy and imaging purposes
US20080081379A1 (en) * 2006-07-13 2008-04-03 Sigler Gerald F Homogeneous double receptor agglutination assay for immunosuppressant drugs
US20080057096A1 (en) 2006-08-29 2008-03-06 Den-Mat Corporation Biocompatible stent
US20080091249A1 (en) * 2006-10-11 2008-04-17 Bwt Property, Inc. Photobiomodulation Apparatus with Enhanced Performance and Safety Features
WO2008118234A2 (en) 2006-11-16 2008-10-02 Anthony Defries A method or means to use or combine plasmonic, thermal, photovoltaic or optical engineering
KR20090122479A (ko) 2007-03-30 2009-11-30 에이전시 포 사이언스, 테크놀로지 앤드 리서치 소수성 양자점의 캡슐화
US9358292B2 (en) 2007-04-08 2016-06-07 Immunolight, Llc Methods and systems for treating cell proliferation disorders
US8376013B2 (en) 2008-03-11 2013-02-19 Duke University Plasmonic assisted systems and methods for interior energy-activation from an exterior source
US7560707B2 (en) * 2007-04-19 2009-07-14 Hewlett-Packard Development Company, L.P. Apparatuses and methods for up-converting electromagnetic radiation
US8093425B2 (en) * 2007-04-30 2012-01-10 Synta Pharmaceuticals Corp. Compounds for treating proliferative disorders
JP2010526986A (ja) 2007-05-11 2010-08-05 エスディーシー マテリアルズ インコーポレイテッド 熱交換器、冷却装置及び冷却方法
JP2009024115A (ja) 2007-07-21 2009-02-05 Tokyo Univ Of Science 蛍光体微粒子−有機色素複合体、及び当該複合体からなる光線力学的治療剤
US20090104212A1 (en) 2007-08-06 2009-04-23 Immunolight Methods and systems for treating cell proliferation disorders using two-photon simultaneous absorption
US8088484B2 (en) * 2007-09-03 2012-01-03 Rohm Co. Ltd. Metallic structure and photodetector
TWI458512B (zh) * 2008-02-21 2014-11-01 Immunolight Llc 利用電漿子增強之光譜療法（ｐｅｐｓｔ）及激子－電漿增強之光療法〈epep〉治療細胞增生病症之組合物及產生自體疫苗之系統
CN102056625B (zh) * 2008-04-04 2015-11-25 免疫之光有限责任公司 用于原位光生物调节的非侵入性系统和方法
JP5682902B2 (ja) 2008-04-23 2015-03-11 独立行政法人産業技術総合研究所 水分散性を有する高発光効率ナノ粒子
US7645318B2 (en) 2008-05-07 2010-01-12 Vive Nano, Inc. Producing nanoparticles using nanoscale polymer templates
US8770203B2 (en) * 2008-07-14 2014-07-08 Immunolight, Llc. Advanced methods and systems for treating cell proliferation disorders
US20110149292A1 (en) * 2008-08-31 2011-06-23 Fujirebio Inc. Apparatus and method for analyzing optical cavity modes
US20110256577A1 (en) * 2008-11-05 2011-10-20 Fujirebio Inc. Method for sensing a biochemical and/or biomechanical process of a biological material and method for analyzing biological materials
US20110253909A1 (en) * 2008-11-07 2011-10-20 Fujirebio Inc. Optical sensing via cavity mode excitations in the stimulated emission regime
US20100224821A1 (en) 2009-03-04 2010-09-09 Bae Systems Information And Electronic Systems Integration Inc. Nanostructure having metal nanoparticles and a method of assembly thereof
WO2010107720A2 (en) * 2009-03-18 2010-09-23 Tuan Vo-Dinh Up and down conversion systems for production of emitted light from various energy sources
AR076361A1 (es) 2009-04-21 2011-06-08 Immunoligtht Llc Composicion farmaceutica. kit. metodos y sistemas de conversion ascendente de energia no invasivos para la fotobiomodulacion in-situ
EP2443439A1 (en) * 2009-06-18 2012-04-25 Fujirebio Inc. Apparatus and method for operating optical microcavity by light emitting diode

Also Published As

Publication number Publication date
JP2012524795A (ja) 2012-10-18
US20190336785A1 (en) 2019-11-07
US9526914B2 (en) 2016-12-27
JP6363288B2 (ja) 2018-07-25
EP2421376B1 (en) 2025-06-04
JP2018149389A (ja) 2018-09-27
US20200078600A1 (en) 2020-03-12
TWI511756B (zh) 2015-12-11
US10384071B2 (en) 2019-08-20
US20230201624A1 (en) 2023-06-29
WO2010123993A1 (en) 2010-10-28
TW201105379A (en) 2011-02-16
JP2016135295A (ja) 2016-07-28
US20150251016A1 (en) 2015-09-10
EP2421376A1 (en) 2012-02-29
US9302116B2 (en) 2016-04-05
JP2018048202A (ja) 2018-03-29
US11324965B2 (en) 2022-05-10
US20110021970A1 (en) 2011-01-27
US10493296B2 (en) 2019-12-03
US20140243934A1 (en) 2014-08-28
JP5908396B2 (ja) 2016-04-26
JP6300854B2 (ja) 2018-03-28
US20170043178A1 (en) 2017-02-16
US20160263393A1 (en) 2016-09-15
EP2421376A4 (en) 2016-04-27
JP6824933B2 (ja) 2021-02-03
US11383098B2 (en) 2022-07-12
US9526913B2 (en) 2016-12-27
SA114350273B1 (ar) 2016-06-23

Similar Documents

Publication Publication Date Title
AR076361A1 (es) Composicion farmaceutica. kit. metodos y sistemas de conversion ascendente de energia no invasivos para la fotobiomodulacion in-situ
Du et al. Near‐infrared‐responsive rare earth nanoparticles for optical imaging and wireless phototherapy
Chen et al. X-ray-activated nanosystems for theranostic applications
Yang et al. Enhancement of photodynamic cancer therapy by physical and chemical factors
Tang et al. Near-infrared excited orthogonal emissive upconversion nanoparticles for imaging-guided on-demand therapy
Wu et al. Dye-sensitized core/active shell upconversion nanoparticles for optogenetics and bioimaging applications
Fan et al. Enhanced afterglow performance of persistent luminescence implants for efficient repeatable photodynamic therapy
Hemmer et al. Optical nanoprobes for biomedical applications: shining a light on upconverting and near-infrared emitting nanoparticles for imaging, thermal sensing, and photodynamic therapy
Park et al. Upconverting nanoparticles: a versatile platform for wide-field two-photon microscopy and multi-modal in vivo imaging
Clement et al. Mechanisms for tuning engineered nanomaterials to enhance radiation therapy of cancer
Duan et al. Recent progress in upconversion luminescence nanomaterials for biomedical applications
Li et al. Recent advances of lanthanide-doped upconversion nanoparticles for biological applications
Zhu et al. Anti-Stokes shift luminescent materials for bio-applications
Feng et al. Aggregation-induced emission (AIE) dots: emerging theranostic nanolights
Sun et al. Engineering persistent luminescence nanoparticles for biological applications: from biosensing/bioimaging to theranostics
Del Rosal et al. Upconversion nanoparticles for in vivo applications: limitations and future perspectives
Kamkaew et al. Scintillating nanoparticles as energy mediators for enhanced photodynamic therapy
Fowley et al. Carbon quantum dot–NO photoreleaser nanohybrids for two-photon phototherapy of hypoxic tumors
US20220193441A1 (en) Energy augmentation structures, emitters or collectors, for use in non-invasive in-situ photobiomodulation
Yu et al. Neodymium‐sensitized nanoconstructs for near‐infrared enabled photomedicine
Sun et al. Upconversion in nanostructured materials: from optical tuning to biomedical applications
US20130195979A1 (en) Core-Excited Nanoparticles and Methods of Their Use in the Diagnosis and Treatment of Disease
Bessière et al. Persistent luminescence materials for deep photodynamic therapy
Arguinzoniz et al. Light harvesting and photoemission by nanoparticles for photodynamic therapy
Gao et al. Modulation of Near‐Infrared Afterglow Luminescence in Inorganic Nanomaterials for Biological Applications

Legal Events

Date Code Title Description
FB Suspension of granting procedure